The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dubchenco E.A.

Federal Center of Brain and Neurotechnologies

Ivanov A.V.

Institute of General Pathology and Pathophysiology

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Spirina N.N.

Yaroslavl State Medical University

Gusev E.I.

Pirogov National Research Medical University

Kubatiev A.A.

Institute of General Pathology and Pathophysiology

Hyperhomocysteinemia and endothelial dysfunction in patients with cerebral vascular and autoimmune diseases

Authors:

Dubchenco E.A., Ivanov A.V., Boyko A.N., Spirina N.N., Gusev E.I., Kubatiev A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(11): 133‑138

DOI: 10.17116/jnevro2019119111133

Read: 3773 times

Download PDF (RU)
Contact the author
Table of contents

HYPERHOMOCYSTEINEMIA AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CEREBRAL VASCULAR AND AUTOIMMUNE DISEASES
HYPERHOMOCYSTEINEMIA AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CEREBRAL VASCULAR AND AUTOIMMUNE DISEASES

To cite this article:

Dubchenco EA, Ivanov AV, Boyko AN, Spirina NN, Gusev EI, Kubatiev AA. Hyperhomocysteinemia and endothelial dysfunction in patients with cerebral vascular and autoimmune diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(11):133‑138. (In Russ.)
https://doi.org/10.17116/jnevro2019119111133

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
The role of gene­tic poly­morphisms in folate meta­bolism genes in the mani­festation of migraine in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):47-52
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Expe­rience of using reamberin for correction of cognitive status in patients with chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):84-88
Quantitative and qualitative asse­ssment of the complete blood count in patients with obstructive sleep apnea and chro­nic ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):95-102
Imme­diate resu­lts of medi­cine Slavinorm treatment in patients with athe­rosclerotic arte­ries diseases of the lower extremities. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):102-108
Abstract:

Endothelial dysfunction today is recognized as one of the leading factors in the pathogenesis of diseases of the central nervous system of various etiologies. Numerous studies have shown the role of hyperhomocysteinemia in the development of endothelial dysfunction and prothrombogenic state. The most important condition in the development of multiple sclerosis (MS) is dysregulation of the blood-brain barrier (BBB) and transendothelial leukocyte migration. It has been proven that homocysteine also contributes to the damage of neurons by the mechanism of excitotoxicity and induction of apoptosis of neurons. These processes can be one of the factors of neurodegenerative brain damage, which plays a leading role in the progression of MS. This review describes the pleiotropic effect of homocysteine on these processes and its role in the pathogenesis of MS.

Keywords:

multiple sclerosis
chronic cerebral ischemia
endothelial dysfunction
homocysteine
hyperhomocysteinemia

Authors:

Dubchenco E.A.

Federal Center of Brain and Neurotechnologies

Ivanov A.V.

Institute of General Pathology and Pathophysiology

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Spirina N.N.

Yaroslavl State Medical University

Gusev E.I.

Pirogov National Research Medical University

Kubatiev A.A.

Institute of General Pathology and Pathophysiology

Accepted:

25.07.2019

Close metadata

References:

  1. Lyros E, Bakogiannis C, Liu Y, Fassbender K. Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer’s disease. Curr Alzheimer Res. 2014;11(1):18-26. 
  2. Gimbrone MA Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118(4):620-636.  https://doi.org/10.1161/CIRCRESAHA.115.306301
  3. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285-1295. https://doi.org/10.1161/CIRCULATIONAHA.106.652859
  4. Jensen HA, Mehta JL. Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. Expert Rev Cardiovasc Ther. 2016;14(9):1021-1033. https://doi.org/10.1080/14779072.2016.1207527
  5. Godo S, Shimokawa H. Endothelial Functions. Arterioscler Thromb Vasc Biol. 2017;37(9):108-114.  https://doi.org/10.1080/14779072.2016.1207527
  6. Canella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37:424-435.  https://doi.org/10.1002/ana.410370404
  7. De Vries HE, Kuiper J, de Boer AG, van Berkel TJC, Brimer DD. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev. 1997;49:143-155. 
  8. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9:6:540-549.  https://doi.org/10.1191/1352458503ms965oa
  9. Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, Sasaki M, Alexander JS. Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler. 2003;9:235-238.  https://doi.org/10.1191/1352458503ms916oa
  10. Lee BPL, Imhof BA. Lymphocyte transmigration in the brain: a new way of thinking. Nature Immunol. 2008;9:117-118.  https://doi.org/10.1038/ni0208-117
  11. Ortiz GG, Pacheco-Moisés FP, Macías-Islas MÁ, Flores-Alvarado LJ, Mireles-Ramírez MA, González-Renovato ED, Hernández-Navarro VE, Sánchez-López AL, Alatorre-Jiménez MA. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014;45(8):687-697.  https://doi.org/10.1016/j.arcmed.2014.11.013
  12. Tanaka R, Iwasaki Y, Koprowski H. Ultrastructural studies of perivascular cuffing cells in multiple sclerosis brain. Am J Pathol. 1975;81:3:467-478. 
  13. Pavlov AYu, Bisaga GN, Decan VS, Rud SD, Gajkova AV, Onishchenko LS. Changes of vessels and cerebral hemodynamic at multiple sclerosis. Vestnik Voenno-Meditsinskoy Academii. 2008;4:66-72. (In Russ.).
  14. Ge Y, Law M, Johnson G, Herbert J, Babb JS, Mannon LJ, Grossman RI. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. Am J Neuroradiol. 2005;26:6:1539-1547.
  15. Gusev EI, Bojko AN, Kol’iak EV, Karalkin AV, Kamchatov PR, Martynov MYu. The impact of microcirculation dysfunction on the clinical presentations of multiple sclerosis in patients above 45 years and the possible ways of correction of the vascular pathology. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2008;108(5):25-31. (In Russ.).
  16. Sparacia G, Agnello F, Gambino A, Sciortino M, Midiri M. Multiple sclerosis: High prevalence of the ‘central vein’ sign in white matter lesions on susceptibility-weighted images. Neuroradiol J. 2018;31(4):356-361.  https://doi.org/10.1177/1971400918763577
  17. D’haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011;10(7):657-666.  https://doi.org/10.1016/s1474-4422(11)70105-3
  18. Spirin NN, Spirina NN, Boyko AN. Von Willebrand factor and adhesion molecules in patients with multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114:2(2):35-39. (In Russ.).
  19. Bolander-Gouaille C. Focus on Homocysteine and the Vitamins involved in its metabolism. Springer Verlag France. 2002.
  20. Lentz SR, Haynes WG. Homocysteine: is it a clinically important cardiovascular risk factor? Cleve Clin J Med. 2004;71(9):729-734. 
  21. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337(4):230-236. 
  22. Homocysteine Studies Collaboration, Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
  23. Dayal S, Lentz SR. Role of Redox Reactions in the Vascular Phenotype of Hyperhomocysteinemic Animals. Antioxid Redox Signal. 2007;18:189-195.  https://doi.org/10.1089/ars.2007.1806
  24. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998;351(9095):36-37.  https://doi.org/10.1016/S0140-6736(05)78090-9
  25. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999;100:1161-1168.
  26. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279-298.  https://doi.org/10.1146/annurev.nu.12.070192.001431
  27. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023-2031 
  28. Rasić-Marković A, Stanojlović O, Hrncić D, Krstić D, Colović M, Susić V, Radosavljević T, Djuric D. The activity of erythrocyte and brain Na+/K+ and Mg2+-ATPases in rats subjected to acute homocysteine and homocysteine thiolactone administration. Mol Cell Biochem. 2009;327(1-2):39-45.  https://doi.org/10.1007/s11010-009-0040-6
  29. Raposo B, Rodríguez C, Martínez-González J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. Atherosclerosis. 2004;177(1):1-8.  https://doi.org/10.1016/j.atherosclerosis.2004.06.015
  30. Undas A, Kolarz M, Kopec G, Glowacki R, Placzkiewicz-Jankowska E, Tracz W. Autoantibodies against N-homocysteinylated proteins in patients on long-term haemodialysis. Nephrol Dial Transplant. 2007;22(6):1685-1689. https://doi.org/10.1093/ndt/gfm068
  31. Yang F, Tan H-M, Wang H. Hyperhomocysteinemia and atherosclerosis. Acta Physiologica Sinica. 2005;57(2):103-114. 
  32. Sen U, Mishra PK, Tyagi N, Tyagi SC. Homocysteine to Hydrogen Sulfide or Hypertension. Cell Biochem Biophys. 2010;57(2-3):49-58.  https://doi.org/10.1007/s12013-010-9079-y
  33. Li JJ, Li Q, Du HP, Wang YL, You SJ, Wang F, Xu XS, Cheng J, Cao YJ, Liu CF, Hu LF. Homocysteine Triggers Inflammatory Responses in Macrophages through Inhibiting CSE-H2S Signaling via DNA Hypermethylation of CSE Promoter. Int J Mol Sci. 2015;16(6):12560-12577. https://doi.org/10.3390/ijms160612560
  34. Lai WK, Kan MY. Homocysteine-Induced Endothelial Dysfunction. Ann Nutr Metab. 2015;67(1):1-12.  https://doi.org/10.1159/000437098
  35. Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia. Front Aging Neurosci. 2018;10:350.  https://doi.org/10.3389/fnagi.2018.00350
  36. Moretti R, Caruso P. The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice. Int J Mol Sci. 2019;20(1):pii: E231. https://doi.org/10.3390/ijms20010231
  37. Li Z, Sun L, Zhang H. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene c677t polymorphism was a risk factor for thrombotic stroke a multicenter case-control study in China. Stroke. 2003;34:2085-2090. https://doi.org/10.1161/01.STR.0000086753.00555.0D
  38. Wu XQ, Ding J, Ay GE. Acute phase homocysteine related to severity and outcome of atherothrombotic stroke. Eur J Int Med. 2013;24:362-367.  https://doi.org/10.1016/j.ejim.2013.06.004
  39. Han L, Wu Q, Wang C. Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: A Population-Based, Prospective Cohort Study Stroke. 2015;46:1777-1786. https://doi.org/10.1161/STROKEAHA.115.009111
  40. Shi Z, Guan Y, Hou YR. Elevated total homocysteine levels in acute ischemic stroke are associated with long-term mortality. Stroke. 2015;46:2419-2425. https://doi.org/10.1161/STROKEAHA.115.009136
  41. Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr. 2016;36:211-239.  https://doi.org/10.1146/annurev-nutr-071715-050947
  42. Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia. Front Aging Neurosci. 2018;10:350.  https://doi.org/10.3389/fnagi.2018.00350
  43. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology. 2002;58:1471-1475. https://doi.org/10.1212/wnl.58.10.1471
  44. Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJ, Lewerin C, Stott DJ, Armitage J, Hankey GJ, Lonn E, Spence JD, Galan P, de Groot LC, Halsey J, Dangour AD, Collins R, Grodstein F; B-Vitamin Treatment Trialists’ Collaboration.. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100:657-666.  https://doi.org/10.3945/ajcn.113.076349
  45. Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;14:643.  https://doi.org/10.1186/1471-2458-14-643
  46. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369(9557):208-216.  https://doi.org/10.1016/S0140-6736(07)60109-3
  47. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci USA. 2013;110(23):9523-9528. https://doi.org/10.1073/pnas.1301816110
  48. Firbank MJ, Narayan SK, Saxby BK, Ford GA, O’Brien JT. Homocysteine is associated with hippocampal and white matter atrophy in older subjects with mild hypertension. Int Psychogeriatr. 2010;22:804-811.  https://doi.org/10.1017/S1041610210000499
  49. Fedin AI, Kaluga AS, Mironova OP, Solov’eva EYu. The role of homocysteine levels in the pathogenesis of cognitive disorders in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2009;109:12(suppl 2):8-12. 
  50. Ansari R, Mahta A, Mallack E, Luo JJ. Hyperhomocysteinemia and neurological disorders: a review. J Clin Neurol. 2014;10(4):281-288.  https://doi.org/10.3988/jcn.2014.10.4.281
  51. Ramsaransing GSM, Fokkema MR, Teelken A, Arutjunyan AV, Koch M, De Keyser J. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:189-192.  https://doi.org/10.1016/j.jcma.2013.07.002
  52. Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P, Trentacosti A, Massenti MF, Savettieri G, Bono A. Blood lipids, homocysteine, stress factors and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis. 2010;9:19.  https://doi.org/10.1186/1476-511X-9-19
  53. Moghaddasi M, Mamarabadi M, Mohebi N, Razjouyan H, Aghaei M. Homocysteine, vitamin B12 and folate levels in Iranian patients with multiple sclerosis: a case control study. Clin Neurol Neurosur. 2013;115:1802-1805. https://doi.org/10.1016/j.clineuro.2013.05.007
  54. Oliveira SR, Flauzino T, Sabino BS, Kallaur AP, Alfieri DF, Kaimen-Maciel DR, Morimoto HK, de Almeida ERD, Lozovoy MAB, Reiche EMV, Dichi I, Simão ANC. Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis. Metab Brain Dis. 2018;33(5):1393-1399. https://doi.org/10.1007/s11011-018-0224-4
  55. Dardiotis E, Arseniou S, Sokratous M, Tsouris Z, Siokas V, Mentis AA, Michalopoulou A, Andravizou A, Dastamani M, Paterakis K, Bogdanos D, Brotis A. Vitamin B12, folate, and homocysteine levels and multiple sclerosis: A meta-analysis. Mult Scler Relat Disord. 2017;17:190-197.  https://doi.org/10.1016/j.msard.2017.08.004
  56. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002;70:694-702.  https://doi.org/10.1002/jnr.10416
  57. Faraci FM, Lentz SR. Hiperhomocysteinemia, oxidative stress and cerebral vascular dysfunction. Stroke. 2004;35:345-347.  https://doi.org/10.1161/01.STR.0000115161.10646.67
  58. Skovierová H, Mahmood S, Blahovcová E, Hatok J, Lehotský J, Murín R. Effect of homocysteine on survival of human glial cells. Physiol Res. 2015;64:747-754 
  59. Skovierová H, Vidomanová E, Mahmood S, Sopková J, Drgová A, Červeňová T, Halašová E, Lehotský J. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int Mol Sci. 2016;17:1733. https://doi.org/10.3390/ijms17101733
  60. Kim JK, Mastronardi FG, Wood DD, Lubman DM, Zand R, Moscarello MA. Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics. 2003;2(7):453-462.  https://doi.org/10.1074/mcp.M200050-MCP200
  61. Russo C, Morabito F, Luise F, Piromalli A, Battaglia L, Vinci A, Trapani Lombardo V, de Marco V, Morabito P, Condino F, Quattrone A, Aguglia U. Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis. J Neurol. 2008;255:64-69.  https://doi.org/10.1007/s00415-007-0668-7
  62. Fahmy EM, Elfayoumy NM, Abdelalim AM, Sharaf SA, Ismail RS, Elshebawy H. Relation of serum levels of homocysteine, vitamin B12 and folate to cognitive functions in multiple sclerosis patients. Int J Neurosci. 2018;128(9):835-841.  https://doi.org/10.1080/00207454.2018.1435538
  63. Teunissen CE, Killestein J, Kragt JJ, Polman CH, Dijkstra CD, Blom HJ. Serum homocysteine levels in relation to clinical progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79:1349-1353. https://doi.org/10.1136/jnnp.2008.151555
  64. Guzel I, Mungan S, Oztekin ZN, Ak F. Is there an association between the expanded disability status scale and inflammatory markers in multiple sclerosis? J Chin Med Assoc. 2016;79:54-57.  https://doi.org/10.1016/j.jcma.2015.08.010
  65. Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D’Onghia M, Paolicelli D, Livrea P, Trojano M. Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. J Neurol. 2012;259(10):2105-2110. https://doi.org/10.1007/s00415-012-6464-z
  66. Dubuisson N, Puentes F, Giovannoni G, Gnanapavan S. Science is 1% inspiration and 99% biomarkers. Mult Scler. 2017;23(11):1442-1452. https://doi.org/10.1177/1352458517709362
  67. Spencer JI, Bell JS, DeLuca GC. Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry. 2018;89(1):42-52.  https://doi.org/10.1136/jnnp-2017-316011
  68. Пступила 24.05.2019 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.